NACLC 22 Educational Session Explores the Rationale for Immune Checkpoint Inhibition

Growing Body of Evidence Highlights Potential Applications for Liquid Biopsy in Clinical Practice

When Perfect is the Enemy of Good: Investigators Compare Rigorous Clinical Trial Data to Real-World Experience

HER2 Mutations Present Unique Challenges in NSCLC

Targeted Therapies Expanding for MET Dysregulation in NSCLC

Undruggable No More: KRAS Experts Review What is Known—and Unknown—About This Challenging Alteration

Regulatory News for Nov. 23, 2022

Guideline-Concordant Surgery, Adjuvant Therapy, and the Promise of Curative-Intent Lung Cancer Surgery: What Are We Up Against?

From the Editor: Looking Back on 2022

In Brief for Jan. 11, 2023

In Brief for January 25, 2023

Increasing Evidence Demonstrates the Usefulness of ctDNA